KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Finished Goods (2016 - 2017)

Amgen has reported Finished Goods over the past 5 years, most recently at $1.1 billion for Q2 2017.

  • Quarterly results put Finished Goods at $1.1 billion for Q2 2017, changed N/A from a year ago — trailing twelve months through Jun 2017 was $1.1 billion (changed N/A YoY), and the annual figure for FY2016 was $912.0 million, up 29.36%.
  • Finished Goods for Q2 2017 was $1.1 billion at Amgen, down from $1.2 billion in the prior quarter.
  • Over the last five years, Finished Goods for AMGN hit a ceiling of $1.2 billion in Q1 2017 and a floor of $705.0 million in Q4 2015.
  • Median Finished Goods over the past 5 years was $914.0 million (2014), compared with a mean of $920.5 million.
  • Biggest five-year swings in Finished Goods: decreased 21.49% in 2015 and later soared 48.02% in 2017.
  • Amgen's Finished Goods stood at $738.0 million in 2013, then rose by 21.68% to $898.0 million in 2014, then decreased by 21.49% to $705.0 million in 2015, then rose by 29.36% to $912.0 million in 2016, then grew by 21.27% to $1.1 billion in 2017.
  • The last three reported values for Finished Goods were $1.1 billion (Q2 2017), $1.2 billion (Q1 2017), and $912.0 million (Q4 2016) per Business Quant data.